



Providence

Medicare Advantage Plans

PROVIDENCE MEDICARE ADVANTAGE PLANS

2025 PRIOR AUTHORIZATION CRITERIA FOR PART B DRUGS:

PHIP ALIGN GROUP PLAN + RX (HMO) AND FLEX GROUP PLAN + RX (HMO-POS) PLANS

Effective 1/1/2025

For more recent information or other questions, please contact Providence Health Assurance Customer Service at 503-574-8000 or 1-800-603-2340 or, for TTY users, 711, seven days a week, between 8 a.m. and 8 p.m. (Pacific Time), or visit ProvidenceHealthAssurance.com/PHIP.

H9047_2025RX_PHA1033_C

Medicare Part B Drug Prior Authorization

Our job as your health plan is to make sure that you receive the right care at the right time and at the most affordable price. Providence Medicare Advantage Plans requires you (or your physician) to get approval for certain medical services, including administration of certain medications, before we will agree to cover the drug for you. This is called “prior authorization.” Sometimes the requirement for getting approval in advance helps guide appropriate use of certain drugs including specialty drugs injected or infused by your provider. If you do not get this approval, your drug might not be covered by the plan.

This document contains the Prior Authorization requirements for certain Part B eligible drugs.

For more recent information or other questions, please contact Providence Health Assurance Customer Service at 503-574-8000 or 1-800-603-2340 (TTY users should call 711), seven days a week, between 8 a.m. and 8 p.m. (Pacific Time), or visit ProvidenceHealthAssurance.com/PHIP.

2025 Medicare Part B Prior Authorization Criteria

| Procedure Code(s) | Medication Name (click the name to view the policy criteria) | Effective Date (if after 1/1/2025) |
|-------------------|--|------------------------------------|
| Q2055 | Abecma (Idecabtagene vicleucel) | |
| J9264 | Abraxane (Paclitaxel protein-bound particles) | |
| J3262 | Actemra (Tocilizumab) | |
| J0791 | Adakveo (Crizanlizumab-tmca) | |
| J9042 | Adcetris (Brentuximab vedotin) | |
| J0172 | Aduhelm (Aducanumab-avwa) | |
| C9167, J3590 | Adzyna (ADAMTS13, recombinant-krhn) | |
| J1931 | Aldurazyme (Laronidase) | |
| J9057 | Aliqopa (Copanlisib) | |
| J9245 | Alkeran (Melfalan hydrochloride) | |
| J7214 | Altuviiio (Factor viii/von willebrand factor complex, recombinant) | |
| J1599 | Alyglo (Immune globulin, gamma(IGG)-stwk) | |
| Q5126 | Alymsys (Bevacizumab-maly) | |
| J1426 | Amondys-45 (Casimersen) | |
| C9399, J9999 | Amtagvi (Lifileucel) | |
| J0225 | Amvuttra (Vutrisiran) | |
| J9999/C9169 | Anktiva (Nogapendekin alfa inbakic-pmln) | |
| J2277 | Aphexda (Motixafortide) | |
| J0256 | Aralast, Prolastin-C, Zemaira (Alpha 1-proteinase inhibitor) | |
| J0881 | Aranesp (Darbepoetin alfa), non-ESRD use | |
| J2793 | Arcalyst (Riloncept) | |
| J9261 | Arranon (Nelarabine) | |
| J9302 | Arzerra (Ofatumumab) | |
| J1554 | Asceniv (Immune globulin) | |
| J9118 | Asparlas (Calaspargase pegol-mknl) | |
| J9029 | Astiladrin (Nadofaragene firadenovec-vncg) | |
| J9035 | Avastin (Bevacizumab) | |
| J3145 | Aveed (Testosterone undecanoate) | |
| Q5121 | Avsola (Infliximab-axxq) | |
| A9590 | Azedra (Iobenguane iodine-131) | |
| J9023 | Bavencio (Avelumab) | |
| J9032 | Beleodaq (Belinostat) | |
| J9036 | Belrapzo (Bendamustine hydrochloride) | |
| J9058 | Bendamustine hydrochloride (apotex) | |
| J9034 | Bendeka (Bendamustine HCl) | |
| J0490 | Benlysta (Belimumab) | |
| J0179 | Beovu (Brolucizumab-dbli) | |
| J0597 | Berinert (C1 esterase inhibitor) | |
| J9229 | Besponsa (Inotuzumab ozogamicin) | |

2025 Medicare Part B Prior Authorization Criteria

| Procedure Code(s) | Medication Name (click the name to view the policy criteria) | Effective Date (if after 1/1/2025) |
|-------------------|---|---------------------------------------|
| J1556 | Bivigam (Immune globulin) | |
| J9037 | Blenrep (Belantamab mafodotin-blmf) | |
| J9039 | Blincyto (Blinatumomab) | |
| J9046 | Bortezomib (Dr. Reddy's) | |
| J9048 | Bortezomib (fresenius kabi) | |
| J9049 | Bortezomib (hospira) | |
| J9051 | Bortezomib (maia) | |
| J0585 | Botox (OnabotulinumtoxinA) | |
| Q2054 | Breyanzi (Lisocabtagene maraleucel) | |
| J0567 | Brineura (Cerliponase alfa) | |
| J2329 | Briumvi (Ublituximab) | |
| J9064 | Cabazitaxel (sandoz) | |
| J1952 | Camcevi (Leuprolide) | |
| Q2056 | Carvykti (Ciltacabtagene autoleucely) | |
| J3590 | Casgevy (Exagamglogene autotemcel) | |
| J1786 | Cerezyme (Imiglucerase) | |
| J3490 | Cetrotide (Cetrotide acetate) | |
| Q5128 | Cimerli (Ranibizumab-eqrn) | |
| J0717 | Cimzia IV (Certolizumab) | |
| J2786 | Cinqair (Reslizumab) | |
| J0598 | Cinryze (C1 esterase inhibitor) | |
| J9286 | Columvi (Glofitamab-gxbm) | |
| J1448 | Cosela (Trilaciclib) | |
| J3247 | Cosentyx IV (Secukinumab) | |
| J0584 | Crysvita (Burosumab-twza) | |
| J1551 | Cutaquig (Immune globulin) | |
| J1555 | Cuvitru (Immune globulin) | |
| J9308 | Cyramza (Ramucirumab) | |
| J0894 | Dacogen (Decitabine) | |
| J9348 | Danyelza (Naxitamab-ggqk) | |
| J9145 | Darzalex (Daratumumab) | |
| J9144 | Darzalex Faspro (Daratumumab/hyaluronidase-fihj) | |
| J0589 | Daxxify (DaxibotulinumtoxinA-lanm) | |
| J0893 | Decitabine (Sun Pharma) | |
| E0607 | Diabetic Durable Medical Equipment (DME) - Glucose Meters | |
| A4253 | Diabetic Durable Medical Equipment (DME) - Test Strips | |
| J7351 | Durysta (Bimatoprost intracameral implant) | |
| J0586 | Dysport (AbobotulinumtoxinA) | |
| J9063 | Elahere (Mirvetuximab soravtansine-gynx) | |
| J1743 | Elaprase (Idursulfase) | |

2025 Medicare Part B Prior Authorization Criteria

| Procedure Code(s) | Medication Name (click the name to view the policy criteria) | Effective Date (if after 1/1/2025) |
|-------------------|---|---------------------------------------|
| J3060 | ElELYso (Taliglucerase alfa) | |
| J1413 | Elevidys (Delandistrogene moxeparvovec-rokl) | |
| J2508 | Elfabrio (Pegunigalsidase alfa-iwxj) | |
| J1950 | Eligard, Lupron Depot (Leuprolide acetate) | |
| J1323 | Elrexfio (Elranatamab-bcmm) | |
| J9269 | Elzonris (Tagraxofusp-erzs) | |
| J3490, J7799 | Empaveli (Pegcetacoplan) | |
| J9176 | Empliciti (Elotuzumab) | |
| J9358 | Enhertu (Fam-trastuzumab deruxtecan-nxki) | |
| J1302 | Enjaymo (Sutimlimab-jome) | |
| J3380 | Entyvio (Vedolizumab), intravenous | |
| J9321 | Epkiny (Epcoritamab-bysp) | |
| J0885 | Epogen, Procrit (Epoetin alfa), non-ESRD use | |
| J9055 | Erbitix (Cetuximab) | |
| J7999 | Estradiol Pellet | |
| J3111 | Evenity (Romosozumab-aqgg) | |
| J1305 | Evkeeza (Evinacumab-dgnb) | |
| J9246 | Evomela (Melphalan hcl/betadex sulfobutyl ether sodium) | |
| J1428 | Exondys-51 (Eteplirsen) | |
| J0177 | Eylea HD (Aflibercept) | |
| J0180 | Fabrazyme (Agalsidase beta) | |
| J0517 | Fasenra (Benralizumab) | |
| J9395 | Faslodex (Fulvestrant) | |
| J1951 | Fensolvi (Leuprolide acetate) | |
| J1572 | Flebogamma (Immune globulin) | |
| J1325 | Flolan, Veletri (Epoprostenol) | |
| J3590 | Follistim AQ (Follitropin b) | |
| J9307 | Folotyn (Pralatrexate) | |
| J9394 | Fulvestrant (fresenius kabi) | |
| J9393 | Fulvestrant (teva) | |
| J9331 | Fyarro (Sirolimus protein-bound particles) | |
| Q5130 | Fylnetra (Pegfilgrastim-pbbk) | |
| S0132 | Fyremadel (Ganirelix acetate) | |
| J1460 | GamaSTAN S/D (Immune globulin) | |
| J9210 | Gamifant (Emapalumab-lzsg) | |
| J1569 | Gammagard Liquid (Immune globulin) | |
| J1566 | Gammagard S-D (Immune globulin) | |
| J1561 | Gammaked (Immune globulin) | |
| J1557 | Gammaplex (Immune globulin) | |
| J1561 | Gamunex-C (Immune globulin) | |

2025 Medicare Part B Prior Authorization Criteria

| Procedure Code(s) | Medication Name (click the name to view the policy criteria) | Effective Date (if after 1/1/2025) |
|-------------------|--|---------------------------------------|
| J0223 | Givlaari (Givosiran) | |
| J0257 | Glassia (Alpha 1 proteinase inhibitor (human)) | |
| J3490, S0126 | Gonal-F (Follitropin alfa) | |
| J9179 | Halaven (Eribulin mesylate) | |
| J1411 | Hemgenix (Etranacogene dezaparvovec-drlb) | |
| J7170 | Hemlibra (Emicizumab-kxwh) | |
| J9248 | Hepzato (Melphalan) | |
| J9355 | Herceptin (Trastuzumab) | |
| J9356 | Herceptin Hylecta (Trastuzumab/hyaluronidase-oysk) | |
| Q5113 | Herzuma (Trastuzumab-pkrb) | |
| J1559 | Hizentra (Immune globulin) | |
| J1575 | Hyqvia (Immune globulin) | |
| J7355 | iDose TR (Travoprost intracameral implant) | |
| J0638 | Ilaris (Canakinumab/pf) | |
| J3245 | Ilumya (Tildrakizumab-asmn) | |
| J9173 | Imfinzi (Durvalumab) | |
| J9347 | Imjudo (Tremelimumab-actl) | |
| J9325 | Imlygic (Talimogene laherparepvec) | |
| J1599 | immune globulin, intravenous, non-lyophilized (e.g. liquid), not otherwise specified | |
| Q5103 | Inflectra (Infliximab-dyyb) | |
| J9319 | Istodax (Romidepsin, lyophilized) | |
| J9207 | Ixempra (Ixabepilone) | |
| J2782 | Izervay (Avacincaptad pegol sodium) | |
| J9281 | Jelmyto (Mitomycin pyelocalyceal instillation) | |
| J9272 | Jemperli (Dostarlimab-gxly) | |
| J0889 | Jesduvroq (Daprodustat) | |
| J9043 | Jevtana (Cabazitaxel) | |
| J9354 | Kadcyla (Ado-trastuzumab emtansine) | |
| J1290 | Kalbitor (Ecallantide) | |
| Q5117 | Kanjinti (Trastuzumab-anns) | |
| J2840 | Kanuma (Sebelipase alfa) | |
| J9271 | Keytruda (Pembrolizumab) | |
| J9274 | Kimmitrak (Tebentafusp-tebn) | |
| J2507 | Krystexxa (Pegloticase) | |
| Q2042 | Kymriah (Tisagenlecleucel) | |
| J9047 | Kyrpolis (Carfilzomib) | |
| J0217 | Lamzede (Velmanase alfa-tycv) | |
| J3590 | Lantidra (Donislecel-jujn) | |
| J0202 | Lemtrada (Alemtuzumab) | |

2025 Medicare Part B Prior Authorization Criteria

| Procedure Code(s) | Medication Name (click the name to view the policy criteria) | Effective Date (if after 1/1/2025) |
|--|---|---------------------------------------|
| J0174 | Leqembi (Lecanemab-irmb) | |
| J1306 | Leqvio (Inclisiran) | |
| J1954 | Leuprolide acetate for depot suspension (ciplā) | |
| J9218 | Leuprolide acetate, per 1 mg | |
| J9119 | Libtayo (Cemiplimab-rwlc) | |
| J3263 | Loqtorzi (Toripalimumab-tpzi) | |
| J0221 | Lumizyme (Alglucosidase alfa) | |
| J9313 | Lumoxiti (Moxetumomab pasudotox-tdfk) | |
| J9350 | Lunsumio (Mosunetuzumab-axgb) | |
| J9217 | Lupron Depot (Leuprolide acetate) | |
| A9513 | Lutathera (Luteium lu177 dotatate) | |
| J3398 | Luxturna (Voretigene neparvovec-rzyl) | |
| J3394 | Lyfgenia (Lovotibeglogene autotemcel) | |
| J9353 | Margenza (Margetuximab-cmkb) | |
| B4104, B4105, B4149, B4150, B4152, B4153, B4154, B4155, B4157, B4158, B4159, B4160, B4161, B4162 | Medical Nutrition (Enteral) - Medicare Part B | |
| J3590 | Menopur (Menotropins) | |
| J3397 | Mepsevii (Vestronidase alfa-vj bk) | |
| J0888 | Mircera (Epoetin beta), non-ESRD use | |
| J9349 | Monjuvi (Tafasitamab-cxix) | |
| Q5107 | Mvasi (Bevacizumab-awwb) | |
| J9203 | Mylotarg (Gemtuzumab ozogamicin) | |
| J0587 | Myobloc (RimabotulinumtoxinB) | |
| J1458 | Naglazyme (Galsulfase) | |
| J0219 | Nexviazyme (Avalglucosidase alfa) | |
| J0725 | Novarel, Pregnyl (Chorionic gonadotropin) | |
| J2796 | Nplate (Romiplostim) | |
| J2182 | Nucala (Mepolizumab) | |
| C9399, J3490 | Nulibry (Fosdenopterin hydrobromide) | |
| Q5122 | Nyvepria (Pegfilgrastim-apgf) | |
| J2350 | Ocrevus (Ocrelizumab) | |
| J1568 | Octagam (Immune globulin) | |
| Q5114 | Ogivri (Trastuzumab-dkst) | |
| J2267 | OmvoH (Mirikizumab-mrkz) | |
| J9205 | Onivyde (Irinotecan liposome) | |
| J0222 | Onpattro (Patisiran) | |
| Q5112 | Ontruzant (Trastuzumab-dttb) | |

2025 Medicare Part B Prior Authorization Criteria

| Procedure Code(s) | Medication Name (click the name to view the policy criteria) | Effective Date (if after 1/1/2025) |
|-------------------|---|------------------------------------|
| J9299 | Opdivo (Nivolumab) | |
| J9298 | Opdualag (Nivolumab/relatlimab-rmbw) | |
| J0129 | Orencia (Abatacept/maltose) intravenous solution | |
| J3490 | Ovidrel (chroric gonadotropin) | |
| J0224 | Oxlumo(Lumasiran sodium) | |
| J9258 | Paclitaxel protein-bound particles (american regent) | |
| J9259 | Paclitaxel protein-bound particles (teva) | |
| J9177 | Padcev (Enfortumab vedotin-ejfv) | |
| J1576 | Panzyga (Immune globulin) | |
| J0208 | Pedmark (Sodium thiosulfate) | |
| J9306 | Perjeta (Pertuzumab) | |
| J9316 | Phesgo (Pertuzumab/trastuzumab/hyaluronidase-zzxf) | |
| A9607 | Pluvicto (Luteium lu-177 vipivotide tetraxetan) | |
| J9309 | Polivy (Polatuzumab vedotin-piiq) | |
| J1203 | Pombiliti (Cipaglucoisidase alfa-atga) | |
| J9295 | Portrazza (Necitumumab) | |
| J9204 | Poteligeo (Mogamulizumab-kpkc) | |
| J3490 | Prevymis (Letermovir) | |
| J1459 | Privigen (Immune globulin) | |
| Q2043 | Provenge (Sipuleucel-T) | |
| J1304 | Qalsody (Tofersen) | |
| J1301 | Radicava (Edaravone) | |
| J0896 | Reblozyl (Luspatercept-aamt) | |
| J1440 | Rebyota (Fecal microbiota, live - jslm) | |
| J1745 | Remicade (Infliximab) | |
| J3285 | Remodulin (Treprostinil) | |
| Q5104 | Renflexis (Infliximab-abda) | |
| Q5106 | Retacrit (Epoetin alfa-epbx), non-esrd use | |
| J3590 | Rethymic (Allogenic processedthymus tissue-agdc) | |
| J3490 | Revatio (Sildenafil), pulmonary hypertension | |
| Q5123 | Riabni (Rituximab-arrx) | |
| J9312 | Rituxan (Rituximab) | |
| J9311 | Rituxan Hycela (Rituximab/hyaluronidase, human recombinant) | |
| J3490 | Rivfloza (Nedosiran sodium) | |
| J1412 | Roctavian (Valoctocogene roxaparvovec-rvox) | |
| J9318 | Romidepsin, non-lyophilized | |
| J0596 | Ruconest (C1 esterase inhibitor, recombinant) | |
| Q5119 | Ruxience (Rituximab-pvvr) | |
| J9061 | Rybrevant (Amivantamab-vmjw) | |

2025 Medicare Part B Prior Authorization Criteria

| Procedure Code(s) | Medication Name (click the name to view the policy criteria) | Effective Date (if after 1/1/2025) |
|---|--|------------------------------------|
| J9021 | Rylaze (Asparaginase, recombinant) | |
| J2998 | Ryplazim (Plasminogen, human-tvmh) | |
| J9333 | Rystiggo (Rozanolixizumab-noli) | |
| J2353 | Sandostatin LAR Depot (Octreotide acetate, microspheres) | |
| J0491 | Saphnelo (Anifrolumab-fnia) | |
| J9227 | Sarclisa (Isatuximab-irf) | |
| J7352 | Scenesse (Afamelanotide implant) | |
| J2502 | Signifor LAR (Pasireotide pamoate) | |
| J1602 | Simponi ARIA (Golimumab) | |
| J2327 | Skyrizi Risankizumab-rzaa intravenous solution | |
| J3590/C9399 | Skysona (Elivaldogene autotemcel) | |
| J1300 | Soliris (Eculizumab) | |
| J1930 | Somatuline Depot (Lanreotide) | |
| J1747 | Spevigo (Spesolimab-sbzo) | |
| J2326 | Spinraza (Nusinersen) | |
| G2082, G2083, S0013 | Spravato (Esketamine) | |
| J3358 | Stelara (Ustekinumab) intravenous solution | |
| Q5127 | Stimufend (Pegfilgrastim-fpgk) | |
| J9226 | Supprelin LA (Histrelin implant) | |
| J2779 | Susvimo (Ranibizumab injection/implant) | |
| J2781 | Syfovre (Pegcetacoplan) | |
| J2860 | Sylvant (Siltuximab) | |
| J3055 | Talvey (Talquetamab-tgvs) | |
| Q2053 | Tecartus (Brexucabtagene autoleucel) | |
| J9022 | Tecentriq (Atezolizumab) | |
| J9380 | Tecvayli (Teclistamab-cqyv) | |
| J3241 | Tepezza (Teprotumumab-trbw) | |
| J3490, J7999, S0189 | Testopel (Testosterone pellet) | |
| J2356 | Tezspire (Tezepelumab-ekko) | |
| J9273 | Tivdak (Tisotumab vedotin-tftv) | |
| J9330 | Torisel (Temsirrolimus) | |
| B4164, B4168, B4172, B4176, B4178, B4180, B4185, B4187, B4189, B4193, B4197, B4199, B4216, B4220, B4222, B4224, B5000, B5100, B5200 | Total Parenteral Nutrition (TPN) - Medicare Part B | |
| Q5116 | Trazimera (Trastuzumab-qyyp) | |
| J9033 | Treanda (Bendamustine HCl) | |

2025 Medicare Part B Prior Authorization Criteria

| Procedure Code(s) | Medication Name (click the name to view the policy criteria) | Effective Date (if after 1/1/2025) |
|-------------------|---|---------------------------------------|
| J3315 | Trelstar (Triptorelin pamoate) | |
| J3316 | Triptodur (Triptorelin) | |
| J9317 | Trodelvy (Sacituzumab govitecan-hziy) | |
| Q5115 | Truxima (Rituximab-abbs) | |
| J3590 | Tyenne (Tocilizumab-aazg) | |
| J2323 | Tysabri (Natalizumab) | |
| J7686 | Tyvaso (Treprostini, inhalation solution) | |
| J9381 | Tzield (Teplizumab-mzvw) | |
| Q5111 | Udenyca (Pegfilgrastim-cbqv) | |
| J1303 | Ultomiris (Ravulizumab-cwvz) | |
| J1823 | Uplizna (Inebilizumab-cdon) | |
| C9399, J3490 | Upravi (Selexipag) | |
| J2777 | Vabysmo (Faricimab) | |
| J9303 | Vectibix (Panitumumab) | |
| Q5129 | Vegzelma (Bevacizumab-adcd) | |
| J9041 | Velcade (Bortezomib) | |
| Q4074 | Ventavis (Iloprost) | |
| J9376 | Veopoz (Pozelelimab-bbfg) | |
| J9025 | Vidaza (Azacitidine) | |
| J1427 | Viltepro (Viltolarsen) | |
| J1322 | Vimizim (Elosulfase alfa) | |
| J9056 | Vivimusta (Bendamustine hydrochloride) | |
| J3385 | VPRIV (Velaglucerase alfa) | |
| J3032 | Vyepi (Eptinezumab-jjmr) | |
| J3401 | Vyjuvek (Beremagene geperpavec-svdt) | |
| J1429 | Vyondys-53 (Golodirsen) | |
| J9332 | Vyvgart (Efgartigimod alfa) | |
| J9334 | Vyvgart Hytrulo (Efgartigimod alfa/hyaluronidase) | |
| J9153 | Vyxeos (Daunorubicin/cytarabine liposomal) | |
| J3490/C9399 | Winrevair (Sotatercept-csrk) | |
| J1558 | Xembify (Immune globulin) | |
| J0218 | Xenpozyme (Olipudase alfa-rpcp) | |
| J0588 | Xeomin (IncobotulinumtoxinA) | |
| J0775 | Xiaflex (Collagenase, clostridium histolyticum) | |
| A9606 | Xofigo (Radium-223) | |
| J2357 | Xolair (Omalizumab) | |
| J9228 | Yervoy (Ipilimumab) | |
| Q2041 | Yescarta (Axicabtagene ciloleucel) | |
| J9352 | Yondelis (Trabectedin) | |
| J9400 | Zaltrap (Ziv-aflibercept) | |

2025 Medicare Part B Prior Authorization Criteria

| Procedure Code(s) | Medication Name (click the name to view the policy criteria) | Effective Date (if after 1/1/2025) |
|-------------------|--|---------------------------------------|
| J9223 | Zepzelca (Lurbinectedin) | |
| Q5120 | Ziextenzo (Pegfilgrastim-bmez) | |
| J0565 | Zinplava (Bezlotoxumab, 10 mg) | |
| Q5118 | Zirabev (Bevacizumab-bvzr) | |
| J9202 | Zoladex (Goserelin acetate implant) | |
| J3399 | Zolgensma (Onasemnogene abeparvovec-xioi) | |
| J9359 | Zynlonta (Loncastuximab tesirine-lpyl) | |
| J3393 | Zynteglo (Betibeglogene autotemcel) | |
| J9345 | Zynyz (Retifanlimab-dlwr) | |